drugset / Trial / NCT07064889
The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
Phase 2
Not yet recruiting
132 enrolled
Peking University People's Hospital
Beijing Aerospace General Hospital · collabBeijing Hospital · collabBeijing Tongren Hospital · collabNavy General Hospital, Beijing · collabQilu Hospital of Shandong University · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
Randomized, open-label, multicenter study to compare the efficacy and safety of Upadacitinib plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with primary immune thrombocytopenia (ITP).
Timeline
- Start
- 2025-07-30
- Primary completion
- 2027-07-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Upadacitinib | Small molecule | 15 mg | Oral |
| Background | Dexamethasone | Small molecule | 40 mg | — |